Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

275 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Upfront allogeneic transplantation versus JAK inhibitor therapy for patients with myelofibrosis: a North American collaborative study.
Maze D, Arcasoy MO, Henrie R, Cerquozzi S, Kamble R, Al-Hadidi S, Yacoub A, Singh AK, Elsawy M, Sirhan S, Smith E, Marcoux C, Viswabandya A, Daly A, Sibai H, McNamara C, Shi Y, Xu W, Lajkosz K, Foltz L, Gupta V. Maze D, et al. Among authors: yacoub a. Bone Marrow Transplant. 2024 Feb;59(2):196-202. doi: 10.1038/s41409-023-02146-6. Epub 2023 Nov 8. Bone Marrow Transplant. 2024. PMID: 37938736 Free PMC article.
Ruxolitinib Therapy Followed by Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation for Myelofibrosis: Myeloproliferative Disorders Research Consortium 114 Study.
Gupta V, Kosiorek HE, Mead A, Klisovic RB, Galvin JP, Berenzon D, Yacoub A, Viswabandya A, Mesa RA, Goldberg J, Price L, Salama ME, Weinberg RS, Rampal R, Farnoud N, Dueck AC, Mascarenhas JO, Hoffman R. Gupta V, et al. Among authors: yacoub a. Biol Blood Marrow Transplant. 2019 Feb;25(2):256-264. doi: 10.1016/j.bbmt.2018.09.001. Epub 2018 Sep 8. Biol Blood Marrow Transplant. 2019. PMID: 30205231 Free PMC article. Clinical Trial.
Correction: Upfront allogeneic transplantation versus JAK inhibitor therapy for patients with myelofibrosis: a North American collaborative study.
Maze D, Arcasoy MO, Henrie R, Cerquozzi S, Kamble R, Al-Hadidi S, Yacoub A, Singh AK, Elsawy M, Sirhan S, Smith E, Marcoux C, Viswabandya A, Daly A, Sibai H, McNamara C, Shi Y, Xu W, Lajkosz K, Foltz L, Gupta V. Maze D, et al. Among authors: yacoub a. Bone Marrow Transplant. 2024 Feb;59(2):295. doi: 10.1038/s41409-023-02194-y. Bone Marrow Transplant. 2024. PMID: 38279008 Free PMC article. No abstract available.
Successful treatment with fludarabine and cyclophosphamide in a VEXAS syndrome patient with associated myelodysplastic syndrome: a case report and systematic review.
Bellman P, Gonzalez-Lugo JD, Shahzad M, Amin MK, Khalid MF, Suleman N, Ahmed N, Singh AK, Yacoub A, Zhang D, McGuirk JP, Mushtaq MU. Bellman P, et al. Among authors: yacoub a. Front Oncol. 2024 Apr 11;14:1383730. doi: 10.3389/fonc.2024.1383730. eCollection 2024. Front Oncol. 2024. PMID: 38665946 Free PMC article.
Safety and efficacy of fedratinib in patients with myelofibrosis previously treated with ruxolitinib: primary analysis of FREEDOM trial.
Gupta V, Yacoub A, Mesa RA, Harrison CN, Vannucchi AM, Kiladjian JJ, Deeg HJ, Fazal S, Foltz L, Mattison RJ, Miller CB, Parameswaran V, Brown P, Hernandez C, Wang J, Talpaz M. Gupta V, et al. Among authors: yacoub a. Leuk Lymphoma. 2024 Sep;65(9):1314-1324. doi: 10.1080/10428194.2024.2346733. Epub 2024 Jun 5. Leuk Lymphoma. 2024. PMID: 38838026 Free article. Clinical Trial.
Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea.
Yacoub A, Mascarenhas J, Kosiorek H, Prchal JT, Berenzon D, Baer MR, Ritchie E, Silver RT, Kessler C, Winton E, Finazzi MC, Rambaldi A, Vannucchi AM, Leibowitz D, Rondelli D, Arcasoy MO, Catchatourian R, Vadakara J, Rosti V, Hexner E, Kremyanskaya M, Sandy L, Tripodi J, Najfeld V, Farnoud N, Papaemmanuil E, Salama M, Singer-Weinberg R, Rampal R, Goldberg JD, Barbui T, Mesa R, Dueck AC, Hoffman R. Yacoub A, et al. Blood. 2019 Oct 31;134(18):1498-1509. doi: 10.1182/blood.2019000428. Blood. 2019. PMID: 31515250 Free PMC article. Clinical Trial.
A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia.
Mascarenhas J, Kosiorek HE, Prchal JT, Rambaldi A, Berenzon D, Yacoub A, Harrison CN, McMullin MF, Vannucchi AM, Ewing J, O'Connell CL, Kiladjian JJ, Mead AJ, Winton EF, Leibowitz DS, De Stefano V, Arcasoy MO, Kessler CM, Catchatourian R, Rondelli D, Silver RT, Bacigalupo A, Nagler A, Kremyanskaya M, Levine MF, Arango Ossa JE, McGovern E, Sandy L, Salama ME, Najfeld V, Tripodi J, Farnoud N, Penson AV, Weinberg RS, Price L, Goldberg JD, Barbui T, Marchioli R, Tognoni G, Rampal RK, Mesa RA, Dueck AC, Hoffman R. Mascarenhas J, et al. Among authors: yacoub a. Blood. 2022 May 12;139(19):2931-2941. doi: 10.1182/blood.2021012743. Blood. 2022. PMID: 35007321 Free PMC article. Clinical Trial.
Use of endpoints in phase III randomized controlled trials for acute myeloid leukemia over the last 15 years: a systematic review.
Shahzad M, Chaudhary SG, Tariq E, Mushtaq AH, Anwar I, Ahmed N, Bansal R, Lutfi F, Balusu R, Abdelhakim H, Yacoub A, Hematti P, Singh AK, McGuirk JP, Mushtaq MU. Shahzad M, et al. Among authors: yacoub a. Leuk Lymphoma. 2023 Feb;64(2):273-282. doi: 10.1080/10428194.2022.2136947. Epub 2022 Oct 25. Leuk Lymphoma. 2023. PMID: 36282773
275 results